Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 4

OlympiA: Data Updates From SABCS 2024

,

Panelists review the recent OlympiA data presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) and discuss how the findings influence their approach to sequencing adjuvant olaparib with other systemic therapies for breast cancer patients.

EP. 1: NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer
EP. 2: Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
EP. 3: BRCA Testing in Early-Stage and Metastatic Breast Cancer
Now Viewing
EP. 4: OlympiA: Data Updates From SABCS 2024

Video content above is prompted by the following:

  • Dr. Shatsky to review and highlight the recent data for OlympiA data presented at SABCS 2024
    • Dr. Shatsky asks Dr. Degen: Based on the OlympiA data, how do you sequence adjuvant olaparib with other systemic therapies?

Related Content:

Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– SubtypesVideo SeriesInsights
Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
Interferon Real- World Treatment Patterns in PV
Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL